New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus (HBV) and progression to cancers other than hepatocellular carcinoma.
The study found that a higher risk of Non-Hodgkin Lymphoma (NHL) and Cholangiocarcinoma was associated with HBV infection in the presence of higher levels of viral replication.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.